RALEIGH, N.C.--(BUSINESS WIRE)--BioDelivery Sciences International, Inc. (Nasdaq: BDSI) announced that data from clinical studies assessing the pharmacokinetics, efficacy, and safety of ONSOLIS™ (formerly referred to as BEMA™ Fentanyl) will be presented at the 2008 Annual Meeting of the American Society of Anesthesiologists (ASA) to be held from October 18 through October 22, 2008, in Orlando, Florida. The scientific poster presentations will include previously presented data from two Phase III clinical studies assessing the efficacy and safety of ONSOLIS™, a potential treatment for breakthrough pain (BTP) in opioid tolerant patients with cancer, as well as data summarizing the favorable pharmacokinetic profile. These data include:
